“Seems like many biotech release interim data nu
Post# of 148286
CYDY has historically not planned trials very well and this is likely why a release of the interim data was not part of the trial protocol. Regardless, I believe it’s time that NP unblind the data at 75% and seek EUA if the DSMC doesn’t make that recommendation (seems likely they will).